RAB18 and Hepatic fibrosis: In the CCl4‐induced liver fibrosis model, we used GYY4137 as a positive control and set two dosing concentrations, low (15 mg kg−1) and high (30 mg kg−1), combined with AAV8‐RAB18KD treatment in mice to systematically explore the central role of RAB18 in DATs‐mediated liver fibrosis treatment.